AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)
19 mai 2021 07h30 HE | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)
11 mai 2021 08h30 HE | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)
11 mai 2021 07h30 HE | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis
13 avr. 2021 08h30 HE | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., April 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
16 mars 2021 07h00 HE | AzurRx BioPharma, Inc.
Top-line data expected by end of Q1 2021 DELRAY BEACH, Fla., March 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)
10 mars 2021 07h00 HE | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Participate in the 33rd Annual Roth Conference
08 mars 2021 07h00 HE | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819
28 janv. 2021 07h00 HE | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 28, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event
05 janv. 2021 08h00 HE | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 05, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted,...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces $8.0 Million Offerings
04 janv. 2021 07h00 HE | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of non-systemic,...